NDA 212194 · Alnylam Pharms INC
Givlaari
Givosiran Sodium · Subcutaneous
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Apr 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Nov 20, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
1 Phase 3, 0 recruiting
FAERS reports
1,559
1,173 serious, 51 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 10, 2025.
GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP). GIVLAARI is an aminolevulinate synthase 1-directed small interfering RNA indicated for the treatment of adults with acute hepatic porphyria (AHP). ( 1 )
Mechanism: Givosiran is a double-stranded small interfering RNA that causes degradation of aminolevulinate synthase 1 ( ALAS1 ) mRNA in hepatocytes through RNA interference, reducing the elevated levels of liver ALAS1 mRNA. This leads to reduced circulating levels of neurotoxic intermediates aminolevulinic acid (ALA) and porphobilinogen (PBG), factors associated with attacks and other disease manifestations of AHP.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 20, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- GIVLAARI · GIVOSIRAN SODIUM EQ 189MG BASE/ML (EQ 189MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Givosiran" as an intervention, any sponsor and status, largest first.
- ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)Pivotal-lookingCompleted
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT03338816 · 94 participants · Start Nov 16, 2017 · Primary completion Jan 31, 2019
Drug: Givosiran; Placebo · For: Acute Hepatic Porphyria; Acute Intermittent Porphyria; Porphyria, Acute Intermittent and 4 more
Sites: Little Rock, Arkansas; San Francisco, California; Boston, Massachusetts · 36 sites in all
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT02452372 · 40 participants · Start May 6, 2015 · Primary completion Sep 6, 2017
Drug: givosiran (ALN-AS1); Sterile Normal Saline (0.9% NaCl) · For: Acute Intermittent Porphyria
Sites: Birmingham, Alabama; San Francisco, California; New York, New York · 6 sites in all
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT02949830 · 16 participants · Start Oct 2016 · Primary completion Nov 5, 2021
Drug: Givosiran · For: Acute Intermittent Porphyria
Sites: San Francisco, California; New York, New York; Galveston, Texas · 5 sites in all
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT03505853 · 10 participants · Start Apr 26, 2018 · Primary completion Nov 16, 2018
Drug: Givosiran; 5-probe cocktail · For: Acute Intermittent Porphyria (AIP); Acute Hepatic Porphyria (AHP); Porphyria, Acute Intermittent and 1 more
Sites: Stockholm, Sweden
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- porphyria acute495
- hospitalisation182
- intentional dose omission119
- nausea118
- product dose omission issue117
- fatigue103
- therapy interrupted103
- pain92
- malaise74
- abdominal pain73
- vomiting67
- ill-defined disorder64
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 75 |
| 2021 | 135 |
| 2022 | 224 |
| 2023 | 267 |
| 2024 | 310 |
| 2025 | 290 |
| 2026 | 258 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Givlaari (Givosiran Sodium)
2024 spending
$20.9M
Beneficiaries
40
341 claims
Per beneficiary
$523,010
$41,591.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,962,651 |
| 2021 | $8,050,650 |
| 2022 | $11,278,250 |
| 2023 | $14,748,145 |
| 2024 | $20,920,401 |
Part B: Givlaari (Givosiran Sodium) · HCPCS J0223
2024 spending
$16.0M
Beneficiaries
43
363 claims
Per beneficiary
$372,177
2024 ASP limit $112.13 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,953,269 |
| 2021 | $10,731,532 |
| 2022 | $14,866,284 |
| 2023 | $16,461,149 |
| 2024 | $16,003,608 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
Balwani M, Sardh E, Ventura P, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.
Yu AM, Choi YH, Tu MJ · Pharmacol Rev 2020 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study.
Sardh E, Balwani M, Rees DC, et al. · Orphanet J Rare Dis 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
Sardh E, Harper P, Balwani M, et al. · N Engl J Med 2019 · Clinical Trial, Phase I, Multicenter Study
- Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.
Ventura P, Bonkovsky HL, Gouya L, et al. · Liver Int 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.
Wang B, Ventura P, Takase KI, et al. · Orphanet J Rare Dis 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Alnylam Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.